Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy
Tao Wang, Desirée Denman, Silvia M. Bacot, et al.
Biomedicines (2022) Vol. 10, Iss. 5, pp. 1181-1181
Open Access | Times Cited: 16

Showing 16 citing articles:

Biomarkers for immunotherapy of hepatocellular carcinoma
Tim F. Greten, Augusto Villanueva, Firouzeh Korangy, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 11, pp. 780-798
Closed Access | Times Cited: 99
Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade
Hidetoshi Hayashi, Kenji Chamoto, Ryusuke Hatae, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 7
Open Access | Times Cited: 17
Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies
Stephanie Pitts, Jeffrey Schlom, Renee N. Donahue
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 9
Exploring Immune Checkpoint Inhibitors: Focus on PD-1/PD-L1 Axis and Beyond
Durre Aden, Samreen Zaheer, Niti Sureka, et al.
Pathology - Research and Practice (2025) Vol. 269, pp. 155864-155864
Closed Access | Times Cited: 1
Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis
Fabio Scirocchi, Lidia Strigari, Alessandra Di Filippo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 22, pp. 14496-14496
Open Access | Times Cited: 32
Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives
Maria Pallozzi, Natalia Di Tommaso, Valeria Maccauro, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4631-4631
Open Access | Times Cited: 20
State of the Art of Immune Checkpoint Inhibitors in Unresectable Pancreatic Cancer: A Comprehensive Systematic Review
Elena Orlandi, Massimo Guasconi, Andrea Romboli, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2620-2620
Open Access
Programmed Cell Death Ligand as a Biomarker for Response to Immunotherapy: Contribution of Mass Spectrometry-Based Analysis
Marco Agostini, Pietro Traldi, Mahmoud Hamdan
Cancers (2025) Vol. 17, Iss. 6, pp. 1001-1001
Open Access
Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis
Linlu Li, Cheng‐Feng Yu, Hongting Xie, et al.
Cancer Medicine (2023) Vol. 12, Iss. 10, pp. 11211-11233
Open Access | Times Cited: 9
Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis
Qian Cui, Wentao Li, Dong Wang, et al.
World Journal of Surgical Oncology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 9
Networks as Biomarkers: Uses and Purposes
Caterina Alfano, Lorenzo Farina, Manuela Petti
Genes (2023) Vol. 14, Iss. 2, pp. 429-429
Open Access | Times Cited: 8
Aspect ratio-dependent dual-regulation of the tumor immune microenvironment against osteosarcoma by hydroxyapatite nanoparticles
Hongfeng Wu, Ruiqi Wang, Shu Li, et al.
Acta Biomaterialia (2023) Vol. 170, pp. 427-441
Open Access | Times Cited: 7
Role of Exosomes in Immunotherapy of Hepatocellular Carcinoma
Bao‐Wen Tian, Cheng‐Long Han, Zhao‐Ru Dong, et al.
Cancers (2022) Vol. 14, Iss. 16, pp. 4036-4036
Open Access | Times Cited: 8
Prognostic significance of circulating exosomal PD-L1 in various malignant tumors: A systematic review and meta-analysis
Wentao Li, Qian Cui, Ting Ge, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Exploring potential predictive biomarkers through historical perspectives on the evolution of systemic therapies into the emergence of neoadjuvant therapy for the treatment of hepatocellular carcinoma
Chuanlei Wang, Wei Feng, Xiaodong Sun, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Preclinical studies of CD103 molecular imaging to guide cancer immunotherapy
Xiaoyu Fan
(2023)
Open Access
Page 1

Scroll to top